SELLAS Life Sciences (SLS) Capital Expenditures Growth (1y) (2014 - 2016)
SELLAS Life Sciences (SLS) Capital Expenditures Growth (1y) (2014 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 143.40% |
| 10 | SELLAS Life Sciences | 1.88 Bn | 1.77 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -101.32% |
| Mar 31, 2016 | -98.80% |
| Dec 31, 2015 | 4,933.33% |
| Sep 30, 2015 | 147.37% |
| Jun 30, 2015 | -6,757.14% |
| Mar 31, 2015 | 2,172.73% |
| Dec 31, 2014 | 103.85% |
| Sep 30, 2014 | -81.73% |